## LB 933

## Revision: 00 FISCAL NOTE LEGISLATIVE FISCAL ANALYST ESTIMATE

ESTIMATE OF FISCAL IMPACT – STATE AGENCIES (See narrative for political subdivision estimates)									
	FY 2024-25		FY 2025-26						
	EXPENDITURES	REVENUE	EXPENDITURES	REVENUE					
GENERAL FUNDS	\$1,760,048		\$1,795,249						
CASH FUNDS									
FEDERAL FUNDS	\$3,131,692		\$3,194,326						
OTHER FUNDS									
TOTAL FUNDS	\$4,891,740		\$4,989,575						

## Any Fiscal Notes received from state agencies and political subdivisions are attached following the Legislative Fiscal Analyst Estimate.

This bill expands Medicaid coverage for continuous glucose monitors (CGMs) to individuals with gestational diabetes and those who meet local coverage determinations under section 1869(F)(2)(B) of the Social Security Act as it existed on January 1, 2024.

The Department of Health and Human Services (DHHS) estimates the total number of Medicaid recipients that would newly qualify for CGMs is 4,086. DHHS assumes 75%, 3,065, will utilize CGMs. The total cost of the first fiscal year is \$9,193,500 assuming 12 months of use at a cost of \$250 per month. DHHS utilizes October 1, 2024 as the implementation date however the bill modifies existing provisions for CGMs therefore it is more appropriate to assume an implementation date of July 1, 2024.

LB 698 that passed in the 2022 session established Medicaid coverage for continuous individuals with a prescription for those with a prescription and who meet medical necessity criteria. The number of recipients estimated that those provisions would apply to was 977 which corresponds to the number of Type 1 diabetics on Nebraska Medicaid. The <u>fiscal note</u> for LB 698 notes that Medicaid is allowed to put controls and limits on covered services and supplies. Medicaid is generally one of the lowest payors therefore it is inconsistent to utilize retail prices to estimate the fiscal impact. The estimate for LB 698 also recognized cost savings in utilizing CGMs, particularly supplies for finger stick monitoring.

Using the DHHS estimate of 75% utilization of the 4,086 newly eligible or 3,065, applying the monthly cost of \$158 and corresponding monthly savings of \$25, plus a 2% increase in FY26, the total estimated fiscal impact is \$4,891,740 in FY25 and \$4,989,575 in FY26. The fund mix is 64.02% Federal Funds which represents a blend of regular Federal Medical Assistance Percentage (FMAP), 57.52% Federal Funds, and the Medicaid expansion match percentage, 90% Federal Funds.

ADMINISTRATIVE SERVICES STATE BUDGET DIVISION: REVIEW OF AGENCY & POLT. SUB. RESPONSE							
LB:	933	933 AM: AGENCY/POLT. SUB: Nebraska Department of Health & Human Services					
REVI	EWED BY:	Ann Linneman	DATE:	2-6-2024	PHONE: (402) 471-4180		
COMMENTS: Concur with the Nebraska Department of Health & Human Services' assessment of fiscal impact.							

LB (1) <u>933</u>

**FISCAL NOTE** 

## ESTIMATE PROVIDED BY STATE AGENCY OR POLITICAL SUBDIVISION State Agency or Political Subdivision Name:(2) Department of Health and Human Services Prepared by: (3) John Meals Date Prepared 2-5-2024 Phone: (5) 471-6719 FY 2024-2025 FY 2025-2026 **EXPENDITURES** REVENUE **EXPENDITURES** REVENUE **GENERAL FUNDS** \$2,481,142 \$3,374,353 **CASH FUNDS** FEDERAL FUNDS \$4,413,983 \$6,003,017 **OTHER FUNDS** TOTAL FUNDS \$0 \$9,377,370 \$0 \$6,895,125

Return by date specified or 72 hours prior to public hearing, whichever is earlier.

Explanation of Estimate:

LB933 requires coverage of continuous glucose monitors (CGMs) for gestational diabetes and requires the Medicare local coverage determinations (LCDs) define the clinical criteria for all CGM eligibility. Medicaid currently covers CGMs for those with gestational diabetes. However, the LCD requirement broadens the Medicaid patients eligible for CGMs.

With LB933, the number of additional patients to be covered for CGMs is 4,086 based on FY23 counts. This fiscal note assumes 75% utilization of covered individuals and an average cost of \$250/month. With an effective date of October 1, 2024, the total expenses for SFY25 would be \$6,895,125 (\$2,481,142 General Funds and \$4,413,983 Federal Funds). Assuming 2% growth for SFY26, the total expenditures would be \$9,377,370 (\$3,374,353 General Funds and \$6,003,017 Federal Funds).

A blended rate of 64.02% was used for both SFY25 and SFY26 based on the recent trending of enrolled Medicaid counts: 80% at "regular" FMAP of 57.52% and 20% at expansion newly rate of 90.00%.

MAJOR OBJECTS OF EXPENDITURE								
PERSONAL SERVICES:								
	NUMBER OF POSITIONS		2024-2025	2025-2026				
POSITION TITLE	24-25	25-26	EXPENDITURES	EXPENDITURES				
Benefits								
Operating								
Travel								
Capital Outlay								
Aid			\$6,895,125	\$9,377,370				
			ψ0,030,120	ψ5,577,570				
Capital Improvements								
TOTAL			\$6,895,125	\$9,377,370				